Tenecteplase (TNK) is Food and Drug Administration approved for reduction of mortality associated with myocardial infarction, but has increasingly been used for treatment of acute ischemic stroke with improved efficacy and similar safety to alteplase. Current guidelines state thrombolytic use in pregnancy should be considered for similar indications as in non-pregnant populations but without increase in significant risk exposure when proper risks and benefits are discussed.

We believe this is one of the first reported cases of TNK administration for acute ischemic stroke in pregnancy. As more medical centers transition to TNK for intravenous thrombolysis in acute ischemic stroke, it is important that we continue to report and evaluate safety outcomes for mother and fetus.